Characteristics of patients who had GVHD and were treated with steroids
Patient no. . | Age, y + mo . | Sex . | Disease . | Donor (sex) . | Cells/kg, × 108 . | ATG . | Growth factor . | ANC recovery, d . | PLT recovery, d . | Conditioning regimen . | Acute GVHD, grade . | Chronic GVHD . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10 + 8/12 | M | HLH | UD (M) | 10.0 | Y | G-CSF | +14 | +18 | BU/TT/FLU | II | No | Alive |
| 2 | 10 | M | ALL | UD (F) | 4.7 | Y | G-CSF | +18 | +22 | TBI/TT/CY | I | Yes, limited | Dead |
| 3 | 9 + 2/12 | M | ALL | UD (M) | 6.2 | Y | G-CSF | +15 | +21 | TBI/TT/CY | II | No | Alive |
| 4 | 7 | M | ALL | UD (F) | 3.0 | Y | G-CSF | +18 | +50 | TBI/TT/CY | II | Yes, extensive | Dead |
| 5 | 17 | F | ALL | Sibl (F) | 3.0 | N | NIL | +16 | +30 | TBI/TT/CY | III | Yes, limited | Alive |
| 6 | 6 + 1/12 | F | AML | UD (M) | 8.0 | Y | NIL | +10 | +29 | BU/CY/L-PAM | II | Nonevaluable | Alive |
Patient no. . | Age, y + mo . | Sex . | Disease . | Donor (sex) . | Cells/kg, × 108 . | ATG . | Growth factor . | ANC recovery, d . | PLT recovery, d . | Conditioning regimen . | Acute GVHD, grade . | Chronic GVHD . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 10 + 8/12 | M | HLH | UD (M) | 10.0 | Y | G-CSF | +14 | +18 | BU/TT/FLU | II | No | Alive |
| 2 | 10 | M | ALL | UD (F) | 4.7 | Y | G-CSF | +18 | +22 | TBI/TT/CY | I | Yes, limited | Dead |
| 3 | 9 + 2/12 | M | ALL | UD (M) | 6.2 | Y | G-CSF | +15 | +21 | TBI/TT/CY | II | No | Alive |
| 4 | 7 | M | ALL | UD (F) | 3.0 | Y | G-CSF | +18 | +50 | TBI/TT/CY | II | Yes, extensive | Dead |
| 5 | 17 | F | ALL | Sibl (F) | 3.0 | N | NIL | +16 | +30 | TBI/TT/CY | III | Yes, limited | Alive |
| 6 | 6 + 1/12 | F | AML | UD (M) | 8.0 | Y | NIL | +10 | +29 | BU/CY/L-PAM | II | Nonevaluable | Alive |
The graft source was bone marrow for all patients.
ANC indicates absolute neutrophil count (day of recovery after transplantation); PLT, platelets (day of recovery after transplantation); HLH, hemophagocytic lymphohistiocytosis; UD, unrelated donor; BU, busulfan, TT, thiotepa; FLU, fludarabine; ALL, acute lymphoblastic leukemia; TBI, total body irradiation; CY, cyclophosphamide; Sibl, sibling; AML, acute myelogenous leukemia; and L-PAM, melphalan.